In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.

Cingolani, A., Torti, L., Pinnetti, C., De Gaetano Donati, K., Murri, R., Tacconelli, E., Larocca, L. M., Teofili, L., Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma, <<AIDS>>, 2010; 24 (15): 2408-2412. [doi:10.1097/QAD.0b013e32833db989] [http://hdl.handle.net/10807/23917]

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma

Cingolani, Antonella;Torti, Lorenza;Pinnetti, Carmela;De Gaetano Donati, Katleen;Murri, Rita;Tacconelli, Evelina;Larocca, Luigi Maria;Teofili, Luciana
2010

Abstract

In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
Inglese
Cingolani, A., Torti, L., Pinnetti, C., De Gaetano Donati, K., Murri, R., Tacconelli, E., Larocca, L. M., Teofili, L., Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma, <<AIDS>>, 2010; 24 (15): 2408-2412. [doi:10.1097/QAD.0b013e32833db989] [http://hdl.handle.net/10807/23917]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/23917
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact